Last reviewed · How we verify
NCT04001894
Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease
Phase 4 trial testing Ticagrelor 90mg in Platelet Reactivity in 50 participants. Completed in 9 December 2020.
9 December 2020
Quick facts
| Lead sponsor | First Affiliated Hospital of Harbin Medical University |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 2 July 2019 |
| Primary completion | 9 December 2020 |
| Estimated completion | 9 December 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- Ticagrelor 90mg — full drug profile →
- Clopidogrel 75mg — full drug profile →
Conditions studied
- Platelet Reactivity — all drugs for Platelet Reactivity →
Sponsor
First Affiliated Hospital of Harbin Medical University
Who can join
18 and older, any sex, with Platelet Reactivity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients with coronary artery disease, but these benefits come at the expense of increased risk of bleeding when compared with aspirin monotherapy. Increased evidence showed that P2Y12 inhibitor monotherapy still maintain antiischemic efficacy while reducing the bleeding risk compared with DAPT. Therefore, the investigators performed this study to observe the efficacy of ticagrelor in comparison to clopidogrel in Chinese patients with stable CAD.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The developmental journey of therapies targeting purine receptors: from basic science to clinical trials.
Han S, Suzuki-Kerr H, Vlajkovic SM, Thorne PR. · · 2022 · cited 9× · PMID 36173587 · DOI 10.1007/s11302-022-09896-w
Verify or expand the search:
- PubMed search for NCT04001894
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ticagrelor 90mg
Trials testing the same drug.
- NCT05476991 — Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atheros · Phase 3 · recruiting
- NCT04718025 — Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndro · Phase 3 · unknown
- NCT05149560 — Ticagrelor Monotherapy After Stenting · Phase 2 · completed
- NCT04738097 — Efficacy of Ticagrelor Plus Aspirin in Mild Non-cardioembolic Ischemic Stroke · Phase 3 · completed
- NCT04739384 — Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS · Phase 3 · completed
Other First Affiliated Hospital of Harbin Medical University trials
Trials by the same sponsor.
- NCT07020195 — QFR-Based Functional SYNTAX Score System in Optimizing Revascularization Strategy for Multivessel Disease · NA · not yet recruiting
- NCT06975592 — Study on the Mechanism of Multi-group Analysis of the Influence of Depression on Common Cardiovascular Diseases · not yet recruiting
- NCT06995456 — Multivariate Analysis and Prediction of Hypertensive Disorder Complicating Pregnancy and Its Related Mechanism · not yet recruiting
- NCT07087093 — Effects of Ketone Esters on Circulating Senescent T Lymphocytes (T Cells) and Inflammation Levels in the Elderly · NA · recruiting
- NCT06565845 — Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04001894 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Harbin Medical University
- Last refreshed: 11 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04001894.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing